(NASDAQ: EWTX) Edgewise Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 16.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.89%.
Edgewise Therapeutics's earnings in 2026 is -$176,010,000.On average, 15 Wall Street analysts forecast EWTX's earnings for 2026 to be $38,905,631, with the lowest EWTX earnings forecast at -$246,732,281, and the highest EWTX earnings forecast at $1,229,142,501. On average, 14 Wall Street analysts forecast EWTX's earnings for 2027 to be -$182,542,294, with the lowest EWTX earnings forecast at -$270,983,745, and the highest EWTX earnings forecast at -$40,670,156.
In 2028, EWTX is forecast to generate -$185,576,417 in earnings, with the lowest earnings forecast at -$274,146,979 and the highest earnings forecast at -$15,816,172.